Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer

Inclusion criteria * Patients (men and women) diagnosed with breast cancer stages I-III initiating first line adjuvant or neoadjuvant therapy with paclitaxel or docetaxel * Ability to understand and the willingness to sign a written informed consent document. * Patients with functional limitations due to musculoskeletal conditions can be included, because these conditions are known to remain stable over the relatively short duration of the study. * Concurrent standard and investigational agents are permissible with the standard chemotherapy drugs. Exclusion Criteria * Prior known chemotherapy or targeted therapy (for breast cancer or other malignancies that is known to be associated with neuropathy in the last 12 months(platinum therapy, bortezomib, vinblastine, etc.) * Prior taxane exposure at any time * Preexisting known diagnosis of any type of neuropathy prior to start of paclitaxel or docetaxel chemotherapy * Pregnant or nursing women. * Unable to give informed consent. * Preexisting lower extremity amputation * Inability to walk or stand without assistance due to any condition * Neuropathic pain medications prior to start of study including gabapentin, pregabalin, amytriptyline, and duloxetine (but initiation of neuropathic pain medications during treatment are permissible) * Patients needing ambulatory assist devices * Back or lower extremity surgery in the last 6 months * Back or lower extremity surgery at any timepoint that interferes with gait and balance per patient or provider report